Progress of Clinical Trials on Bone Marrow Mesenchymal Stem Cells for Prevention and Therapy of Graft-Versus-Host Disease.
10.7534/j.issn.1009-2137.2015.06.050
- Author:
Dan-Li ZHONG
1
;
San-Fang TU
1
;
Yu-Hua LI
2
Author Information
1. Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong Province, China.
2. Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong Province, China. E-mail: liyuhua2011gz@163.com.
- Publication Type:Journal Article
- MeSH:
Bone Marrow Cells;
Bone Marrow Transplantation;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Hematopoietic Stem Cells;
Humans;
Mesenchymal Stem Cell Transplantation
- From:
Journal of Experimental Hematology
2015;23(6):1808-1812
- CountryChina
- Language:Chinese
-
Abstract:
Graft-versus-host disease (GVHD) is a major complication following allogenetic hematopoietic stem cell transplantation, which shows a great threat to patients' survival and life quality. Along with multiple differentiation potential to various types of progenitor cells, bone marrow mesenchymal stem cells (BMMSC) have been confirmed to possess low immunogenicity and exert favorable immunomodulation. The recent studies show that the safety and high efficiency of BMMSC to prevent and cure GVHD greatly improved survival rate of the hosts. The most recent progress on prevention and therapy of GVHD is summarized in this review based on biology of BMMSC and pathogenesis of GVHD, so as to provide the effective evidence for further research.
